The US biotech Alumis has announced the price of its initial public offering (IPO), set at 16 euros per share for a total of 13,125,000 ordinary shares. This price is at the lower limit of the previously established price range. All shares are offered by Alumis itself.
In addition, the Company has granted the underwriters a 30-day over-allotment option, allowing them to purchase up to 1,968,750 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. .
Alumis shares will begin trading on the Nasdaq on June 28, 2024, under the symbol ‘ALMS’. The offering is expected to close on July 1, 2024. In addition to the shares sold in the IPO, Alumis has agreed to sell an additional 2,500,000 shares of its common stock in a concurrent private placement at $16 per share to AyurMaya Capital Management, one of its existing investors. Completion of the private placement is contingent upon the closing of the initial public offering.
Alumis expects gross proceeds from the IPO and the concurrent private placement, net of underwriting discounts, commissions and offering and private placement expenses, to be $250 million, excluding any exercise by the underwriters of their option to purchase additional shares.
